LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT + STUDY

Authors
Category Primary study
ConferenceAnnual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine, AANEM 2022
Year 2022
This article has no abstract
Epistemonikos ID: 1f0b7a7da452cad15850e96bf041bb0adbdc1f14
First added on: Jan 10, 2026